ArticleAAPS PharmSciTech2026
The Application of Machine Learning in the Development of Co-Amorphous Dry Powder Inhalation.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides improving drug solubility and stability, co-amorphous systems (COAMS) have recently been reported to enhance the pulmonary delivery efficiency of dry powder inhalation (DPI), offering a novel approach to the development of DPI. Conventional drug formulation development utilizes trial-and-error experiments, which require a laborious workload and resources. Moreover, the correlation of forming COAMS to enhanced pulmonary deposition remains underrepresented. Therefore, we proposed applying multiple machine learning (ML) models to the development of co-amorphous DPIs. In this study, we first constructed the database of COAMS through literature mining and then preprocessed the dataset with a molecular representation method. Subsequently, we successfully developed and evaluated the predictive performance of multiple ML models (i.e., logistic regression, random forests, XGBoost, LightGBM, and support vector machines) for forming a co-amorphous system. The five ML models' performance varied, yet all achieved satisfactory predictive accuracy (ACC) of around 0.80 in the testing subset. Specifically, LightGBM exhibited the highest ACC of 0.790 in cross-validation and 0.845 in the testing subset. In addition, SHapley Additive ex Planations (SHAP) analysis revealed that several molecular features (i.e., API_EState_VSA10, Co-former_BCUT2D_MRHI) are critical for models' prediction. More importantly, we conducted experimental validation by using salbutamol sulfate and indomethacin as model drugs to prepare co-amorphous DPIs based on the fine-tuned LightGBM model. The co-amorphous DPIs showed satisfactory aerodynamic performance with fine particle fractions of 41.87%-69.30%. In conclusion, we successfully demonstrated the feasibility of ML for guiding the formation of co-amorphous DPIs, further facilitating the development process in the future.
Indexed as
Identifiers
42086959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.